|
Apr 25
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Apr 6
|
After a Serious Setback, Is Verve Therapeutics a Buy?
|
|
Apr 4
|
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
|
|
Apr 3
|
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
|
|
Apr 2
|
Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects
|
|
Apr 2
|
Verve Falls as Gene-Editing Trial Paused on Safety Issues
|
|
Apr 2
|
UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
|
|
Apr 2
|
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
|
|
Apr 2
|
Verve Therapeutics Announces Updates on its PCSK9 Program
|
|
Apr 2
|
Verve pauses base editing trial, shifts strategy after treatment side effect
|
|
Mar 28
|
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 21
|
3 Stocks That Could Be the Next Big Thing in Gene Editing
|
|
Feb 15
|
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
|
|
Feb 12
|
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
|
|
Jan 4
|
Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024
|
|
Jan 2
|
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 29
|
Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade
|
|
Dec 29
|
Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet
|
|
Dec 1
|
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
|
|
Nov 29
|
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
|